Brian Parkin, MD
Hematology & Oncology · Orlando, FLNPI 1568582393
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,535 of the $15,575 with a category attached, or 67.6%. Daiichi Sankyo Inc. accounts for 70.2% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2024 at $11,228 and has fallen 91.3% since, to $982 in 2025.
Across 62 payments — averaging $251.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$11K
- Servier Pharmaceuticals LLC$2K
- Adaptive Biotechnologies Corporation$665
- National Marrow Donor Program$215
- AbbVie$177
- Johnson & Johnson$163
- plus $1K from 14 others
Across 136 payments — averaging $1850.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Daiichi Sankyo Inc.$159K
- Syndax Pharmaceuticals, Inc.$70K
- AbbVie$16K
- Cepheid$6K
What the payments were for
- Consulting fees$10,53568%
- Travel & lodging$2,25514%
- Food & beverage$2,78518%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 21 | $10,926 |
| Servier Pharmaceuticals LLC | 2 | $2,310 |
| Adaptive Biotechnologies Corporation | 9 | $665 |
| National Marrow Donor Program | 1 | $215 |
| AbbVie | 3 | $177 |
| Johnson & Johnson | 2 | $163 |
| Janssen Research & Development, LLC | 1 | $146 |
| Incyte Corporation | 1 | $130 |
| Amgen | 1 | $130 |
| Gilead | 1 | $124 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $124 |
| Tempus AI, Inc | 2 | $117 |
| Legend Biotech USA Inc. | 3 | $95 |
| Sanofi-aventis U.S. LLC | 2 | $47 |
| Medline Industries LP | 1 | $43 |
| Pfizer | 2 | $41 |
| Beigene USA, Inc. | 2 | $35 |
| Stemline Therapeutics Inc. | 1 | $34 |
| Genmab U.S., Inc. | 1 | $30 |
| Syndax Pharmaceuticals, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,575 in reported general payments places this provider in the 65th percentile of 694 hematology & oncology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Orlando
- Mark SocinskiOrlando$2.4M
- Tarek MekhailOrlando$2.2M
- Daniel LandauOrlando$1.8M
- Shahram MoriOrlando$952K
- Sajeve ThomasOrlando$639K
- Nikita ShahOrlando$470K
- Martin DietrichRockledge$6.2M
- Edgardo SantosFort Lauderdale$2M
- Wassim McHaylehAltamonte Springs$1.5M
- Edith PerezJacksonville$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.